knowledge -WSS

knowledge

author：hotspot 2025-09-28 09:06:00 - browse：227

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Just how do doctors, lawmakers, and the public define abortion?

WSS

Deliver public health messages at the right time

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

How a small hospital in rural Puerto Rico survived Hurricane Maria

AltruBio raises $225 million to develop ulcerative colitis drug

Brain technologies pose threats that are all too real, experts warn

With psoriasis trial ahead, Alumis raises $259 million

explore

knowledge

knowledge

Guidelines to prevent youth baseball injuries need more muscle

Has Bernie Sanders reached the limit of his pharma bullying effort?

Psychedelics group wrestles with new pharma identity

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Medicare details structure of new drug price negotiation program

AltruBio raises $225 million to develop ulcerative colitis drug

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Amylyx ALS drug failure raises questions and concerns

What does generative AI mean for health care? We asked experts

Black vets could get higher VA benefits if race not used in lung test

focus

PBM executives asked to testify by House panel

Deliver public health messages at the right time

Has Bernie Sanders reached the limit of his pharma bullying effort?

NEJM study link tiny plastics in blood vessels to heart problems

As billionaires fund anti

Just how do doctors, lawmakers, and the public define abortion?

hotspot

explore

explore

entertainment